175 related articles for article (PubMed ID: 38563855)
1. Sex differences in adverse events in Medicare individuals ≥ 66 years of age post glioblastoma treatment.
Dmukauskas M; Cioffi G; Waite KA; Sloan AE; Neff C; Price M; Ostrom QT; Barnholtz-Sloan JS
J Neurooncol; 2024 May; 168(1):111-123. PubMed ID: 38563855
[TBL] [Abstract][Full Text] [Related]
2. Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma.
Barnholtz-Sloan JS; Williams VL; Maldonado JL; Shahani D; Stockwell HG; Chamberlain M; Sloan AE
J Neurosurg; 2008 Apr; 108(4):642-8. PubMed ID: 18377240
[TBL] [Abstract][Full Text] [Related]
3. Racial/ethnic differences in survival among elderly patients with a primary glioblastoma.
Barnholtz-Sloan JS; Maldonado JL; Williams VL; Curry WT; Rodkey EA; Barker FG; Sloan AE
J Neurooncol; 2007 Nov; 85(2):171-80. PubMed ID: 17530174
[TBL] [Abstract][Full Text] [Related]
4. Effect of health disparities on overall survival of patients with glioblastoma.
Mandel JJ; Youssef M; Nam J; Patel AJ; Jalali A; Ludmir EB; Liu D; Wu J; Armstrong G; Huse J; Bondy M; de Groot JF
J Neurooncol; 2019 Apr; 142(2):365-374. PubMed ID: 30671709
[TBL] [Abstract][Full Text] [Related]
5. Malignant pleural mesothelioma characteristics and outcomes: A SEER-Medicare analysis.
Taioli E; Wolf A; Alpert N; Rosenthal D; Flores R
J Surg Oncol; 2023 Jul; 128(1):134-141. PubMed ID: 36932968
[TBL] [Abstract][Full Text] [Related]
6. Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014.
Ostrom QT; Cote DJ; Ascha M; Kruchko C; Barnholtz-Sloan JS
JAMA Oncol; 2018 Sep; 4(9):1254-1262. PubMed ID: 29931168
[TBL] [Abstract][Full Text] [Related]
7. Impact of timing to initiate adjuvant therapy on survival of elderly glioblastoma patients using the SEER-Medicare and national cancer databases.
Zhu P; Du XL; Hwang LY; Lairson D; Li R; Esquenazi Y; Zhu JJ
Sci Rep; 2023 Feb; 13(1):3266. PubMed ID: 36841851
[TBL] [Abstract][Full Text] [Related]
8. Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study.
Roy S; Lakritz S; Schreiber AR; Kuna EM; Bradley CJ; Kondapalli L; Diamond JR
Eur J Cancer; 2024 Jan; 196():113426. PubMed ID: 38000217
[TBL] [Abstract][Full Text] [Related]
9. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy.
Freedman RA; Vaz-Luis I; Barry WT; Lii H; Lin NU; Winer EP; Keating NL
Breast Cancer Res Treat; 2014 Jun; 145(2):491-501. PubMed ID: 24756187
[TBL] [Abstract][Full Text] [Related]
10. Adult cerebellar glioblastoma: understanding survival and prognostic factors using a population-based database from 1973 to 2009.
Adams H; Chaichana KL; Avendaño J; Liu B; Raza SM; Quiñones-Hinojosa A
World Neurosurg; 2013 Dec; 80(6):e237-43. PubMed ID: 23395851
[TBL] [Abstract][Full Text] [Related]
11. Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis.
Wen J; Chen W; Zhu Y; Zhang P
BMC Cancer; 2021 Jan; 21(1):81. PubMed ID: 33468109
[TBL] [Abstract][Full Text] [Related]
12. Improved survival time trends for glioblastoma using the SEER 17 population-based registries.
Koshy M; Villano JL; Dolecek TA; Howard A; Mahmood U; Chmura SJ; Weichselbaum RR; McCarthy BJ
J Neurooncol; 2012 Mar; 107(1):207-12. PubMed ID: 21984115
[TBL] [Abstract][Full Text] [Related]
13. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare.
Zhang X; El-Serag HB; Thrift AP
Cancer Causes Control; 2021 Apr; 32(4):317-325. PubMed ID: 33394207
[TBL] [Abstract][Full Text] [Related]
14. Hospitalization burden and survival among older glioblastoma patients.
Arvold ND; Wang Y; Zigler C; Schrag D; Dominici F
Neuro Oncol; 2014 Nov; 16(11):1530-40. PubMed ID: 24778086
[TBL] [Abstract][Full Text] [Related]
15. Age-adjusted Charlson comorbidity index in recurrent glioblastoma: a new prognostic factor?
Barz M; Bette S; Janssen I; Aftahy AK; Huber T; Liesche-Starnecker F; Ryang YM; Wiestler B; Combs SE; Meyer B; Gempt J
BMC Neurol; 2022 Jan; 22(1):32. PubMed ID: 35062885
[TBL] [Abstract][Full Text] [Related]
16. Associations Between Female Sex and Treatment Patterns and Outcomes for Muscle-invasive Bladder Cancer.
Grajales V; Bandari J; Hale NE; Yabes JG; Turner RM; Fam MM; Sabik LM; Gingrich JR; Davies BJ; Jacobs BL
Urology; 2021 May; 151():169-175. PubMed ID: 32673679
[TBL] [Abstract][Full Text] [Related]
17. A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999.
Chakrabarti I; Cockburn M; Cozen W; Wang YP; Preston-Martin S
Cancer; 2005 Dec; 104(12):2798-806. PubMed ID: 16288487
[TBL] [Abstract][Full Text] [Related]
18. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
[TBL] [Abstract][Full Text] [Related]
19. Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer.
Nipp R; Tramontano AC; Kong CY; Pandharipande P; Dowling EC; Schrag D; Hur C
Cancer Med; 2018 Feb; 7(2):525-535. PubMed ID: 29322643
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for glioblastoma therapy associated complications.
Ening G; Osterheld F; Capper D; Schmieder K; Brenke C
Clin Neurol Neurosurg; 2015 Jul; 134():55-9. PubMed ID: 25942630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
